Submit Your Request Now
- Overview
- Panels List
- Applications
- Workflow
- Why Creative Proteomics
- Demo
- Sample Requirements
- Case Study
- FAQ
Why Focus on the Mouse Proteome with Olink?
Mouse Proteome Assay Service is designed to advance translational biomedicine by delivering high-precision, large-scale protein quantification. By leveraging Olink's technology, this platform becomes an indispensable tool for researchers using mice to model human biology, discover biomarkers, and develop future therapies:
- Enables Precise & Longitudinal Immune Profiling in Murine Models – Olink's Mouse-Specific Panels allow multiplexed measurement of 43 immune-related proteins from only 1 µL of sample. This enables repeated sampling in longitudinal studies within the same animal, improving statistical power and reducing inter-individual variability. Researchers gain a high-resolution view of immune responses over time during disease progression or treatment.
- Supports Robust Disease Modeling and Mechanistic Research – Mouse models are essential for understanding disease mechanisms of human conditions like cancer, autoimmune disorders, neurodegeneration, and metabolic diseases. Olink's high specificity and sensitivity help identify key pathway activations and protein signatures reflective of human disease states.
- Bridges Preclinical Mouse Data to Human Clinical Applications – Reliable mouse proteomic data is critical for translational research, predicting human responses and validating therapeutic targets. Olink's platform is used across drug development stages, from early discovery to clinical validation. Using the same PEA technology in both mouse and human studies improves cross-species comparability and confidence in translating findings.
- Ideal for Biobanking and Large-Scale Cohort Studies Involving Mouse Models – Although commonly applied in human biobanks, Olink's approach is equally powerful for large murine cohort studies. With minimal sample consumption, it supports high-throughput proteomics in repositories of mouse sera, plasma, or tissue samples It enables population-level proteomic studies in genetically diverse or engineered mouse strains, mimicking human population genomics initiatives.
- Provides High-Quality, Reproducible Data for Systems Biology and Multi-Omics Integration – Olink's PEA technology is known for low coefficient of variation (CV) and high reproducibility, which is essential for reliable biomarker discovery. It facilitates proteogenomic integration. This is especially useful in identifying causal proteins and pathways underlying genetic associations found in murine models.
Selecting the Right Panel for Mouse Proteome Studies
Mapping the mouse proteome demands both comprehensive coverage and high specificity. We provide a tiered panel strategy optimized exclusively for mouse model research, enabling deep proteomic analysis across diverse biological contexts with species-matched reagents and validated targets:
- Discovery Scale – Mouse Exploratory Panel
Designed for large-scale, untargeted proteome screening in murine samples, this panel enables comprehensive analysis of diverse biological processes, including signal transduction, metabolic regulation, immune response, and development. It is optimized for hypothesis-generating research, facilitating the identification of novel pathways and dynamic protein changes in mouse models, and is particularly suited for large-cohort studies and biobanking initiatives.
- Validation Scale – Mouse Cytokine Panel
This focused multiplex assay provides high-throughput, precise quantification of key immune mediators such as cytokines and chemokines, which are central to murine inflammatory and immune responses. Optimized for targeted validation, it supports rigorous hypothesis testing in immunology, infectious disease, and immunotherapy research using mouse models.
Together, these panels enable a seamless workflow from discovery to validation within a mouse-specific framework, ensuring high specificity, reduced cross-reactivity risks, and enhanced data quality.
Here is a list of recommended panels we offer:
Table. List of Olink Panels
| Platforms | Recommended Olink Panels |
| Target 96 | Olink Target 96 Mouse Exploratory Panel |
| Target 48 | Olink Target 48 Mouse Cytokine Panel |
Additional Options
In addition to the panels above, we also offer panels for human-focused research:
- Explore HT
- Explore 3072 (3072 proteins)
- Explore 1536 (1536 proteins)
- Explore 384
- Target 96
- Olink Target 96 Cell Regulation Panel
- Olink Target 96 Immuno-Oncology
- Olink Target 96 Oncology II Panel
- Olink Target 96 Oncology III Panel
- Olink Target 96 Inflammatory
- Olink Target 96 Neuro Exploratory
- Olink Target 96 Organ Damage Panel
- Olink Target 96 Immune Response
- Olink Target 96 Development Panel
- Olink Target 96 Metabolism
- Olink Target 96 Cardiometabolic
- Olink Target 96 Cardiovascular II Panel
- Olink Target 96 Cardiovascular III Panel
- Olink Target 96 Neurology
- Target 48
- Custom Olink Flex systems
Our team can assist in designing an integrated Olink–Mouse Proteome Assay strategy tailored to your project goals.
Applications of Mouse Proteome Assay
Our Mouse Proteome Assay Service is specifically designed to address critical questions in preclinical and translational research using murine models. By integrating high-plex discovery and targeted, species-specific validation, it empowers the following mouse-focused applications:
- Preclinical Biomarker Discovery at Scale
Quantify 43 carefully selected immune-related proteins from only 1 µL of mouse plasma or serum. This enables robust biomarker identification in longitudinal murine studies, supporting research in disease mechanisms, treatment efficacy, and toxicity, while minimizing animal use and facilitating ethical, high-quality data generation.
- Immune, Inflammatory & Metabolic Disease Research
Uncover circulating protein dynamics in mouse models of autoimmune disease, chronic inflammation, metabolic syndrome, and neuroinflammation. The Target 48 Mouse Cytokine Panel offers deep insights into conserved immune pathways critical for translating murine findings to human conditions.
- Immuno-Oncology & Cancer Mechanisms
Profile the tumor microenvironment and systemic immune responses in murine cancer models. This panel supports studies in immunotherapy and helps identify cytokine signatures predictive of tumor behavior or treatment outcomes.
- Neurological Disease and Aging in Mice
Track low-abundance neuroinflammatory and neurodegeneration-related proteins in murine models of Alzheimer's, Parkinson's, or aging. The assay's high sensitivity allows detection of subtle, dynamic changes in central nervous system processes.
- Multi-Omics Integration for Mechanistic Insight
Combine murine proteomic data with genomic and transcriptomic profiles to uncover protein quantitative trait loci (pQTLs) and signaling pathways. This systems biology approach strengthens causal inference in mouse studies and supports biomarker validation and drug target identification.
Workflow of Mouse Proteome Assay
Figure 1: Workflow of Olink's Mouse Proteome Assay Service.
Why Creativ Proteomics
Olink's mouse-specific proteomic empower researchers to uncover robust, biologically relevant insights in murine models. CPR offers a tailored solution for addressing unique challenges in preclinical and immunology-focused studies:
Mouse-Optimized Assay Technology with Superior Performance
- Species-Specific PEA Technology: Our Olink's proprietary PEA platform is exclusively validated for mouse samples, ensuring high specificity and minimal cross-reactivity against murine antigens. This enables accurate quantification of low-abundance proteins in complex matrices like mouse serum, plasma, and tissue fluids.
- Comprehensive Mouse Panels: Tailored panels provide focused coverage of murine immune pathways, inflammation markers, and disease mechanisms, enabling deep phenotyping in oncology, neurology, and metabolic research.
Multi-Omics Integration for Mechanistic Insights in Mouse Models
- Proteogenomic Applications: Integrates seamlessly with genomic and transcriptomic data to identify murine protein quantitative trait loci (pQTLs) and elucidate conserved pathways in immuno-oncology, neuroinflammation, and metabolic diseases.
- Cross-Species Translational Relevance: Bridges mouse-to-human research by highlighting evolutionarily conserved biomarkers, enhancing the predictive value of murine data for human clinical applications
Rigorous Quality Assurance for Murine Research
- Validation in Mouse Samples: All assays undergo species-specific validation for precision, reproducibility, and dynamic range (10 logs), ensuring reliability in longitudinal murine studies and multi-omics collaborations.
- Consistency in Low-Volume Samples: Maintains high data quality even with minute volumes, reducing inter-animal variability and supporting robust statistical analysis.
Workflow Efficiency and Customization for Mouse Studies
- Custom Panel Flexibility: We offer tailored mouse panels for hypothesis-driven validation or broad exploratory screening, aligning with diverse research needs from discovery to translational validation.
- Integration with Murine Multi-Omics Platforms: Compatible with NGS and mass spectrometry workflows, enabling combined proteomic-genomic analyses without requiring specialized instrumentation.
Together, Our Olink's mouse-specific platform combines unmatched technical rigor, species-relevant design, and translational adaptability to address critical gaps in preclinical research.
Demo Results: Olink Mouse Proteome Assay
Figure 2: Heatmap showing average changes of top 20 regulated proteins between control and ExpOF mice at d14 and d14 + 3. (Lund, C., et al. 2024)
Figure 3: Protein expression analyses of ileal tissue digests by proximity extension assay (OLINK mouse exploratory panel. (Wills, J.W., et al. 2025)
Figure 4: Plasma protein levels of circulating cytokines as measured by the Olink Target 96 Mouse Exploratory panel. (Gkioni, L., et al. 2025)
Sample Requirements for Mouse Proteome Assay
1. Supported Sample Types
- Plasma (recommended anticoagulants: EDTA or citrate; avoid heparin due to potential interference).
- Serum
- Other biomatrices: Tissue homogenates, cell lysates, CSF (cerebrospinal fluid), and other biofluids. For non-standard samples (e.g., tissue lysates), consult the service provider for validation.
2. Sample Volume
- Minimum volume: 1 μL per assay.
- Recommended total submission: ≥50 μL per sample to account for pipetting losses, repeat assays, and quality control.
3. Sample Concentration and Quality
- Concentration: No strict concentration requirement due to PEA's high sensitivity (detection down to fg/mL).
- Quality checks: Avoid hemolysis (especially for blood-derived samples), as it may interfere with protein measurements. For tissue or cell lysates, ensure clear supernatants after centrifugation (no debris or lipids). Samples should be free of precipitates or clots.
4. Storage and Shipping
- Storage: -80°C immediately after collection.
- Shipping: Transport on dry ice (ensure no thawing during transit). Use validated shipping containers to maintain temperature.
Case Study
Title: Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker
Journal: Nat Commun
Year: 2024
- Background
- Methods
- Results
Glioblastoma (GBM) remains the most aggressive primary brain tumor in adults, with limited efficacy from standard therapies and a median survival of only 15 months. Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematological malignancies but faces significant challenges in solid tumors like GBM due to immunosuppressive microenvironments dominated by glioma-associated microglia and macrophages (GAMs). The CD47-SIRPα axis, a key phagocytosis checkpoint, is often exploited by tumor cells to evade immune clearance. While CD47 blockade can reactivate GAM phagocytosis, systemic anti-CD47 monotherapy suffers from toxicity and poor bioavailability in solid tumors. This study engineered EGFRvIII-targeting CAR T cells to constitutively secrete a high-affinity CD47 blocker—signal regulatory protein gamma-related protein (SGRP)—aiming to overcome antigen heterogeneity and myeloid-mediated immunosuppression in GBM.
To profile systemic immune responses following CAR T cell therapy, a targeted proteomic analysis was performed using Olink's PEA technology. Plasma samples were collected from mice 24 hours after the second intratumoral CAR T cell treatment (day 15 post-tumor implantation). The panel quantified 92 immune-oncology-related proteins across two complementary datasets comprising 54 plasma samples from individual mice. Baseline protein levels were established using plasma from healthy control mice. Data normalization involved bridging samples between datasets and applying cyclic loess normalization. Differential expression analysis was conducted using Mann-Whitney U tests with Benjamini-Hochberg correction to identify significantly altered proteins between treatment groups.
Olink proteomic analysis revealed that aEGFRvIII-SGRP CAR T cell treatment induced a distinct peripheral inflammatory signature compared to control groups, with significant upregulation of the myeloid chemoattractant CCL3 (Fig. 4b). Additionally, differential expression analysis between SGRP-secreting and non-secreting CAR T cells identified elevated levels of CXCL1, CXCL8, GZMA, TNFRSF21, TNFSF14, and VEGFA in the aEGFRvIII-SGRP group (Fig. 4c). Despite the robust association of CCL3 with enhanced treatment efficacy, subsequent in vivo neutralization experiments demonstrated that CCL3 blockade did not impair therapeutic outcomes, suggesting redundancy in chemokine signaling or compensation by other immune mediators (Supplementary Fig. 5f).
Figure 5: Differential expression analysis of aEGFRvIII-SGRP CAR vs aEGFRvIII CAR treatment groups. (Martins, T.A., et al. 2024)
Figure 6: Box plots with individual data points showing the NPX of significant innate immune surrogate markers in plasma. (Martins, T.A., et al. 2024)
FAQs
Is validation required?
While Olink assays are highly validated, orthogonal methods (e.g., ELISA) are recommended for confirming critical biomarkers.
Are there limitations?
The Olink Mouse Proteome Assay has certain limitations to consider. Firstly, it exhibits species specificity, meaning it is specifically designed and optimized for mouse samples and is not validated or guaranteed for use with samples from other species. Secondly, regarding panel customization, the available Mouse Exploratory Panel (Target 96) is a predefined set of 92 proteins focused on key biological processes and disease mechanisms in mouse models. While Olink offers broad portfolio of proteomics solutions, custom panels tailored to specific research needs require thorough evaluation and validation, which may involve additional time, cost, and experimental verification to ensure performance reliability.
References
- Lund, C., Ranea-Robles, P., Falk, S. et al. Protection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4R. Nat Commun 15, 1192 (2024).
- Wills, J.W., Dabrowska, A., Robertson, J. et al. Immunocompetent cell targeting by food-additive titanium dioxide. Nat Commun 16, 6067 (2025).
- Gkioni, L., Nespital, T., Baghdadi, M. et al. The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan. Nat Aging 5, 1249–1265 (2025).
- Martins, T.A., Kaymak, D., Tatari, N. et al. Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker. Nat Commun 15, 9718 (2024).